Who to call at Silo Pharma, Inc., and when
Fundz watches for the moments Silo Pharma, Inc. starts buying, and tells you who to reach.
- An alert the day Silo Pharma, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Silo Pharma, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Silo Pharma, Inc.. With Fundz connected, it knows.
Silo Pharma, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
silopharma.comAI Executive Summary
AI-powered analysis of 8-K filing content
Silo Pharma's shareholders approved at its October 24, 2025 annual meeting an increase in the equity plan share reserve from 470,000 to 1,400,000 shares, re-elected four directors, ratified Salberg & Company as auditor, and authorized a board-discretionary reverse split between 1-for-2 and 1-for-20 exercisable until October 24, 2026. The plan increase and reverse split authority signal potential dilution and a capital structure change.
Key Takeaways
Shareholders approved raising the share reserve under the Amended and Restated 2020 Omnibus Equity Incentive Plan from 470,000 to 1,400,000 shares, nearly tripling the pool available for equity awards
Shareholders authorized the board to effect a reverse stock split at any ratio from 1-for-2 to 1-for-20, at the board's sole discretion, without reducing authorized shares, with execution permitted un
3 more takeaways
Related Filings (9)
9 more filings from Silo Pharma, Inc. in the last 90 days
Filing Overview
What This Means
Silo Pharma, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.